Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 1,500 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $78.18, for a total transaction of $117,270.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Steven Shak also recently made the following trade(s):
- On Monday, September 10th, Steven Shak sold 5,500 shares of Genomic Health stock. The shares were sold at an average price of $63.05, for a total transaction of $346,775.00.
Shares of Genomic Health stock traded up $1.53 during trading hours on Thursday, hitting $75.50. The company had a trading volume of 475,170 shares, compared to its average volume of 294,643. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of 7,550.00 and a beta of 0.40. Genomic Health, Inc. has a twelve month low of $26.54 and a twelve month high of $92.18.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million during the quarter, compared to analysts’ expectations of $94.27 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. Genomic Health’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) EPS. Analysts expect that Genomic Health, Inc. will post 1.06 earnings per share for the current year.
Several brokerages have recently issued reports on GHDX. BidaskClub cut shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Raymond James began coverage on shares of Genomic Health in a report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Zacks Investment Research cut shares of Genomic Health from a “buy” rating to a “hold” rating in a report on Thursday, August 30th. Finally, Canaccord Genuity restated a “buy” rating and issued a $82.00 target price (up previously from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $48.33.
A number of large investors have recently modified their holdings of the stock. Clearbridge Investments LLC acquired a new stake in Genomic Health during the 3rd quarter worth $12,880,000. Vanguard Group Inc. boosted its stake in Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after purchasing an additional 337,664 shares during the period. Kepos Capital LP acquired a new stake in Genomic Health during the 3rd quarter worth $1,864,000. Nordea Investment Management AB boosted its stake in Genomic Health by 17.5% during the 3rd quarter. Nordea Investment Management AB now owns 79,128 shares of the medical research company’s stock worth $5,557,000 after purchasing an additional 11,776 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in Genomic Health by 38.0% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 242,839 shares of the medical research company’s stock worth $17,052,000 after purchasing an additional 66,873 shares during the period. Hedge funds and other institutional investors own 89.21% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Genomic Health, Inc. (GHDX) Insider Steven Shak Sells 1,500 Shares” was first reported by Zolmax and is the property of of Zolmax. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://zolmax.com/investing/genomic-health-inc-ghdx-insider-steven-shak-sells-1500-shares/2745604.html.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Recommended Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.